A Bright Horizon: Staying Up To Date with New and Emerging Therapies For Atopic Dermatitis (Webcourse)

Approximately one-third of patients with atopic dermatitis (AD) have severe disease that requires systemic treatment directed at controlling immune responses. In recent years, novel therapies targeting the underlying pathophysiology of AD have been approved with many more emerging, but many clinicians lack familiarity with these new and emerging agents as well as related mechanisms of action and safety and efficacy profiles. Furthermore, clinicians often underestimate AD disease severity and the impact on patient’s quality of life (QoL), leading to undertreatment.

This activity “A Bright Horizon: Staying Up To Date with New and Emerging Therapies For Atopic Dermatitis” aims to provide allergists and dermatologists with up-to-date information on management of moderate to severe AD, including the health burden of uncontrolled disease, identification of patients with more severe disease who require treatment escalation, evidence-based use of newer targeted therapies, and how emerging therapies may impact AD management in the near term.

Jointly provided by the Potomac Center for Medical Education and Rockpointe

Patient Resources provided by

This activity is supported through an educational grant from Pfizer Inc.